MedTrace Logo

Chidamide Plus DCAG for Relapsed/Refractory AML

NCT02886559 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-02-14

No results posted yet for this study

Summary

Despite advances in understanding the complexities of acute myeloid leukaemia (AML), the treatment of refractory or relapsed AML (rrAML) remains a daunting clinical challenge.The investigators designed a new regimen, including chidamide, decitabine, aclarubincin, cytarabine and G-CSF, to treat rrAML.

Conditions

Interventions

DRUG

Chidamide plus DCAG regimen

chidamide, decitabine, aclarubicin, cytarabine and G-CSF

Sponsors & Collaborators

  • Navy General Hospital, Beijing

    collaborator OTHER

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Li Yu, MD. Ph.D · Chinese PLA General Hospital

  • Li-Xin Wang, MD. Ph.D. · Navy General Hospital, Beijing, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-06-30
Completion
2019-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02886559 on ClinicalTrials.gov